{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:17:44Z","timestamp":1784751464475,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["1627 PAVIA CSA2016S"],"award-info":[{"award-number":["1627 PAVIA CSA2016S"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["1627 PAVIA CSA2016S"],"award-info":[{"award-number":["1627 PAVIA CSA2016S"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dolutegravir (DTG) is an Integrase Strand Transfer Inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV infection. It is available in a number of pharmaceutical preparations including the fixed-dose combination (TLD) containing tenofovir (300\u00a0mg)\u2009+\u2009lamivudine (300\u00a0mg)\u2009+\u2009dolutegravir (50\u00a0mg). In 2018, Eswatini adopted TLD as the preferred first-line HIV treatment regimen for adults and adolescents as per WHO recommendations. From March 2019 to March 2020, the National Pharmacovigilance Center (NPC) in Eswatini received 8 reports of hyperglycaemia associated with the use of DTG. This study was conducted to investigate if Eswatini NPC database included cases suggestive of causality between dolutegravir and hyperglycaemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A qualitative synthesis of information from the Eswatini national pharmacovigilance database from March 2019 to March 2020 was conducted to investigate a casual association between hyperglycaemia and dolutegravir.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All reports with dolutegravir containing regimen and suspected Adverse Event of hyperglycaemia in the period of March 2019 to March 2020 were included in the study. Seven of the reports were serious (resulted in hospitalization and one case concerned optic neuritis, leading to blindness). Two patients had a medical history of diabetes while the rest of the patients had never experienced hyperglycaemia before starting dolutegravir. For all the reports, the time to onset of hyperglycaemia ranges from 2\u20135\u00a0months after the initiation of DTG. None of the patients discontinued the use of DTG. All the patients were treated with oral hypoglycaemic medication. In severe cases, patients were treated with intravenous normal saline and ringer lactate as well as rapid-acting insulins. All patients are currently stable on oral hypoglycaemic drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Cases that support causality between dolutegravir containing regimen and hyperglycaemia were found. These cases were mainly serious. Based on these findings it is recommended that healthcare professionals (HCPs) actively screen all patients for risk factors of hyperglycaemia before DTG initiation. In addition, it is important that HCPs are aware of the possible association between DTG and hyperglycaemia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-022-00481-0","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:27:39Z","timestamp":1669328859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-1025","authenticated-orcid":false,"given":"Alemayehu L.","family":"Duga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibongile","family":"Magongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siphesihle","family":"Nhlabatsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis O.","family":"Ladwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"H\u00e4rmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le\u00e0n","family":"Rolfes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"481_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.03.004","author":"T Cihlar","year":"2016","unstructured":"Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016. https:\/\/doi.org\/10.1016\/j.coviro.2016.03.004.","journal-title":"Curr Opin Virol"},{"key":"481_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","volume":"10","author":"E De Clercq","year":"2010","unstructured":"De Clercq E. Antiretroviral drugs. Curr Opin Pharmacol. 2010;10:507\u201315.","journal-title":"Curr Opin Pharmacol"},{"key":"481_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/1060028013513558","volume":"48","author":"RC Rathbun","year":"2014","unstructured":"Rathbun RC, Lockhart SM, Miller MM, Liedtke MD. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection. Ann Pharmacother. 2014;48:395\u2013403.","journal-title":"Ann Pharmacother"},{"key":"481_CR4","unstructured":"USFDA. Drug Approval Package: Brand Name (Generic Name) NDA # [Internet]. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204790Orig1s000TOC.cfm. Accessed 14 Apr 2021."},{"key":"481_CR5","unstructured":"World Health Organization. WHO Model List of Essential Medicines. 2017. http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/. Accessed 18 May 2020."},{"key":"481_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040382","author":"S Duwal","year":"2012","unstructured":"Duwal S, Sch\u00fctte C, von Kleist M. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0040382.","journal-title":"PLoS One"},{"issue":"1","key":"481_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1128\/AAC.00842-09","volume":"54","author":"S Min","year":"2010","unstructured":"Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010Jan;54(1):254\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"481_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.antiviral.2009.09.014","volume":"85","author":"T Cihlar","year":"2010","unstructured":"Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antivir Res. 2010;85:39\u201358.","journal-title":"Antivir Res"},{"key":"481_CR9","unstructured":"Dolutegravir | Integrase Inhibitors | Pediatric ARV | AIDSinfo. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/2\/pediatric-arv\/435\/dolutegravir. Accessed 1 Jun 2020."},{"key":"481_CR10","unstructured":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating. 2018."},{"key":"481_CR11","unstructured":"The Kingdom of Eswatini M of H. 2018 Eswatini Integrated HIV Management Guidelines. Mbabane; 2018."},{"key":"481_CR12","unstructured":"The Kingdom of Eswatini M of H. LMIS data. Mbabane; 2020."},{"key":"481_CR13","unstructured":"FDA. Dolutegravir | FDA Label - Tablet (film coated) | AIDSinfo. https:\/\/aidsinfo.nih.gov\/drugs\/509\/dolutegravir\/167\/professional#invalid_link. Accessed 28 May 2020."},{"key":"481_CR14","unstructured":"ICH. ICH Official web site\u202f: ICH History. 2020. https:\/\/www.ich.org\/page\/meddra. Accessed 15 Apr 2021."},{"key":"481_CR15","doi-asserted-by":"crossref","unstructured":"Suri P, Aurora T. Hyperglycemia. In: Observation Medicine: Principles and Protocols. Cambridge University Press; 2017. p. 225\u201330.","DOI":"10.1017\/9781139136365.044"},{"key":"481_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-3-2","author":"S Kalra","year":"2011","unstructured":"Kalra S, Kalra B, Agrawal N, Unnikrishnan A. Understanding diabetes in patients with HIV\/AIDS diabetology and metabolic syndrome. BioMed Central. 2011. https:\/\/doi.org\/10.1186\/1758-5996-3-2.","journal-title":"BioMed Central"},{"key":"481_CR17","doi-asserted-by":"crossref","unstructured":"Brewer JP. Research Triangle Park [Internet]. Vol. 368, Nature. 1994. www.fda.gov\/medwatch. 8 May 2020.","DOI":"10.1038\/368169a0"},{"key":"481_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30042-4","author":"M Lamorde","year":"2020","unstructured":"Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F, et al. Dolutegravir-associated hyperglycaemia in patients with HIV. Lancet HIV. 2020. https:\/\/doi.org\/10.1016\/S2352-3018(20)30042-4.","journal-title":"Lancet HIV"},{"key":"481_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jac\/dkx365","volume":"73","author":"M McLaughlin","year":"2018","unstructured":"McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob Chemother. 2018;73:258\u201360.","journal-title":"J Antimicrob Chemother"},{"key":"481_CR20","unstructured":"Janet Lo et al. DOLUTEGRAVIR AND INSULIN RESISTANCE\u2014CROI Conference. Conference on Retroviruses and Opportunistic Infections; 2019. https:\/\/www.croiconference.org\/abstract\/dolutegravir-and-insulin-resistance\/. 8 May 2020."},{"key":"481_CR21","unstructured":"World Health Organization. Update of recommendations on first-and second-line antiretroviral regimens. 2019. http:\/\/apps.who.int\/bookorders. 17 May 2020."},{"key":"481_CR22","unstructured":"FDA. Highlights of Prescribing information. 2013. www.fda.gov\/medwatch. 17 May 2020."},{"key":"481_CR23","doi-asserted-by":"crossref","unstructured":"EMA. Summary of product characteristics. In: Pharmaceutical Medicine. 2014. p. 87\u20139.","DOI":"10.1093\/med\/9780199609147.003.0027"},{"issue":"13","key":"481_CR24","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/01.aids.0000181011.62385.91","volume":"19","author":"TT Brown","year":"2005","unstructured":"Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the multicenter AIDS cohort study. AIDS. 2005Sep 2;19(13):1375\u201383.","journal-title":"AIDS"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-022-00481-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:29:35Z","timestamp":1669328975000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-022-00481-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1186\/s12981-022-00481-0","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted retrospectively from Pharmacovigilance report obtained for clinical purposes. Ethical approval was obtained from Eswatini Health and Human Research Review Board (EHHRRB) on January 26, 2021 with reference number of SHR274\/2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}